Literature DB >> 6782927

Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon.

M B Kahaleh, I Osborn, E C LeRoy.   

Abstract

Von Willebrand factor activity and factor VIII/von Willebrand factor (fVIII/vWf) antigen concentrations were evaluated in 17 patients with scleroderma, nine patients with Raynaud's phenomenon, and eight control volunteers. Higher circulating levels of both activities were seen: von Willebrand factor, 374% +/- 40% (percent of control values) in scleroderma patients, 502% +/- 104% in patients with Raynaud's phenomenon and 102% +/- 6% in control subjects (p less than 0.005, scleroderma versus control): fVIII/vWf antigen, 255% +/- 24% in scleroderma patients; 271% +/- 46% in patients with Raynaud's phenomenon, and 99% +/- 4% in control subjects (p less than 0.005, scleroderma versus control). Because endothelial cells synthesize and secrete both substances, the role of endothelial injury in vitro was investigated. Wound injury induced a 344% +/- 33% increase in von Willebrand factor and a 115% +/- 5% increases in fVIII/vWf antigen; cold injury induced 644% +/- 66% and 150% +/- 10% increases, and cytotoxic endothelial injury induced 1055% +/- 83% and 185% +/- 20% increases. In five patients with scleroderma, cold exposure led to a further increase in both activities. The observed increase of both activities in scleroderma and Raynaud's phenomenon may reflect in-vivo endothelial injury and regeneration in these related conditions.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6782927     DOI: 10.7326/0003-4819-94-4-482

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  47 in total

Review 1.  Raynaud's phenomenon: epidemiology and risk factors.

Authors:  Liana Fraenkel
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 2.  Pharmacodynamic monitoring of cyclosporin.

Authors:  W M Awni
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

3.  Raised concentrations of von Willebrand factor antigen in systemic sclerosis.

Authors:  A D Blann; K J Illingworth; M I Jayson
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

4.  Circulating von Willebrand factor in inflammatory bowel disease.

Authors:  T R Stevens; J P James; N J Simmonds; D A McCarthy; I F Laurenson; P J Maddison; D S Rampton
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

5.  Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study.

Authors:  S Furukawa; S Yasuda; O Amengual; T Horita; T Atsumi; T Koike
Journal:  Ann Rheum Dis       Date:  2006-08       Impact factor: 19.103

Review 6.  Raynaud's phenomenon: its relevance to scleroderma.

Authors:  J J Belch
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 7.  The endothelium: its role in scleroderma.

Authors:  J D Pearson
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

8.  Disseminated intravascular coagulation with renal and liver damage as the predominant manifestations of recurrent relapses in systemic juvenile rheumatoid arthritis.

Authors:  D Schwartz; M Averbuch; A Pines; R Kornovsky; Y Levo
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

Review 9.  Dermatology.

Authors:  M H Rustin
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

10.  Von Willebrand factor antigen in assessment of vasculitis in patients with connective tissue diseases.

Authors:  J Kloczko; A Kuryliszyn-Moskal; K Bernacka; M Bielawiec; B Cylwik; P Radziwon
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.